Abogen
Total Raised
$1.134BInvestors Count
40Deal Terms
1Funding, Valuation & Revenue
5 Fundings
Abogen has raised $1.134B over 5 rounds.
Abogen's latest funding round was a Series C - II for $300M on November 29, 2021.
Abogen's latest post-money valuation is from November 2021.
Sign up for a free demo to see Abogen's valuations in November 2021 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
11/29/2021 | Series C - II | $300M | 15 | |||
8/20/2021 | Series C | |||||
4/7/2021 | Series B | |||||
11/5/2020 | Series A | |||||
2/26/2020 | Seed VC |
Date | 11/29/2021 | 8/20/2021 | 4/7/2021 | 11/5/2020 | 2/26/2020 |
|---|---|---|---|---|---|
Round | Series C - II | Series C | Series B | Series A | Seed VC |
Amount | $300M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 15 |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Abogen Deal Terms
1 Deal Term
Abogen's deal structure is available for 1 funding round, including their Series C - II from November 29, 2021.
Round | Series C - II |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series C - II |
Abogen Investors
40 Investors
Abogen has 40 investors. 5Y Capital invested in Abogen's Series C - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/20/2021 | 11/29/2021 | 2 Series C, Series C - II (2021) | Venture Capital | China | ||
11/29/2021 | 11/29/2021 | 1 Series C - II | Asset/Investment Management | South Korea | ||
11/29/2021 | 11/29/2021 | 1 Series C - II | Venture Capital | California | ||
Other | China | |||||
Private Equity | Hong Kong |
First funding | 8/20/2021 | 11/29/2021 | 11/29/2021 | ||
|---|---|---|---|---|---|
Last Funding | 11/29/2021 | 11/29/2021 | 11/29/2021 | ||
Investor | |||||
Rounds | 2 Series C, Series C - II (2021) | 1 Series C - II | 1 Series C - II | ||
Board Seats | |||||
Type | Venture Capital | Asset/Investment Management | Venture Capital | Other | Private Equity |
Location | China | South Korea | California | China | Hong Kong |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Abogen to Competitors
NeoCura is committed to building a Ribonucleic acid (RNA) drug platform. It has built a multi-omics big data collection platform and multi-bionics database to perform in-depth drug target mining and fully automated drug design based on Artificial intelligence (AI) algorithms and core bioinformatic technologies. Through application in clinical innovative RNA drug development and next-generation and safe clinical precision diagnosis and treatment, it provides patients with one-stop full-cycle solutions from screening, diagnosis, and treatment to efficacy monitoring. It was founded in 2017 and is based in Beijing, China.
Loading...